

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

## **Causal Effects of Herpesvirus-Associated Antibodies on Autoimmune neuroinflammatory diseases: Mendelian Randomization Study**

**Shujun Sun<sup>1¶</sup>, Yiyong Wen<sup>2¶</sup>, Pan tang<sup>2</sup>, Fan xie<sup>2</sup>, Jun wen<sup>2</sup>, Anding Xu<sup>3\*</sup>**

1. Department of Neurology and Stroke Center, The First Affiliated Hospital of Jinan University;  
Guangzhou, Guangdong 510632, China.

2.Department of Neurology, Changde Hospital, Xiangya School of Medicine, Central South University ( The first people's hospital of Changde city)  
No. 388 Renmin East Road, Changde City, Hunan Province, China.

3.:Department of Neurology and Stroke Center ,  
Key Lab of Guangzhou Basic and Translational Research of Pan-vascular Diseases  
The First Affiliated Hospital of Jinan University  
Guangzhou, Guangdong 510632, China

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

22 \* Corresponding author

23 E-mail: [tlil@jnu.edu.cn](mailto:tlil@jnu.edu.cn).

24

25 † Shujun Sun and Yiyong Wen have contributed equally to this work.

26

## 27 Abstract

28 **Background:** Herpesvirus infections may trigger Autoimmune neuroinflammatory  
29 diseases (ANDs), but their causal role is uncertain. This study used Mendelian  
30 randomization (MR) to investigate the causal effects of herpesvirus antibodies on ANDs.

31 **Methods:** We assessed 22 herpesvirus antibodies and five ANDs—multiple sclerosis  
32 (MS), neuromyelitis optica (NMO), myasthenia gravis (MG), Guillain-Barré syndrome  
33 (GBS), and chronic inflammatory demyelinating polyneuropathy (CIDP)—using five MR  
34 methods. MR-PRESSO, MR-Egger, and Cochran's Q statistic identified pleiotropy and  
35 heterogeneity. Bonferroni correction set the significance threshold at  $P < 4.545e-04$ .

36 Validation used UK Biobank and FinnGen data, with meta-analysis for inconsistent  
37 results. **Results:** Significant positive causal effects were found for Epstein-Barr virus  
38 encoded nuclear antigen-1 (EBV EBNA-1) (OR=3.009), EBV viral capsid antigen (VCA)  
39 p18 ( OR=8.700 ) , and human herpesvirus 7(HHV7) U14 (OR=3.359) antibody levels  
40 on MS risk, and HHV7 U14 (OR=10.641), Varicella zoster virus glycoprotein E and  
41 glycoprotein I(VZV gE and gI) (OR=17.220) antibody levels on NMO risk. VZV gE and gI  
42 ( OR=2.542 ) antibodies increased MG risk, while EBV ZEBRA ( OR=0.592 ) reduced  
43 MS risk. Negative effects of EBV EA-D and ZEBRA antibodies on NMO were also noted.

44 Validation confirmed the effects of EBV EBNA-1, EBV VCA p18 antibodies on MS, and  
45 VZV gE and gI on antibody MG, while EBV ZEBRA and HHV7 U14 antibodies effects on  
46 MS were not validated. **Conclusions:** The study suggests a causal link between specific  
47 herpesvirus antibodies and the risk of MS, NMO, and MG.

48

49 **Keywords:** Autoimmune neuroinflammatory diseases, multiple sclerosis, neuromyelitis  
50 optica, myasthenia gravis, Epstein-Barr virus, human herpesvirus, varicella zoster virus,  
51 antibody

52

## 53 Introduction

54 Autoimmune neuroinflammatory diseases (ANDs) are a category of disorders in  
55 which the immune system mistakenly targets and attacks the nervous system, resulting  
56 in inevitable structural and functional damage[1, 2]. Autoimmune neurological diseases  
57 (ANDs) include mainly multiple sclerosis (MS), neuromyelitis optica (NMO), Guillain-Barr  
58 é syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and  
59 myasthenia gravis (MG). MS and NMO affect the central nervous system (CNS), GBS  
60 and CIDP affect the peripheral nervous system (PNS), and MG affects the  
61 neuromuscular junction (NMJ). These conditions lead to neuronal or axonal damage,  
62 demyelination, damage to the nerve-muscle junction and other pathological changes [3,  
63 4].

64 The incidence and prevalence of autoimmune diseases are increasing worldwide  
65 every year, but the exact causes of these diseases remain unknown; however, it is

66 thought that a mixture of genetic and environmental factors play a role in their  
67 development [5]. Infections seem to be a common trigger for autoimmune diseases [6].

68 Several viruses of the Herpesviridae family have been implicated as an important  
69 risk factor for ANDs, Epstein-Barr virus (EBV) has been implicated as a major cause of  
70 multiple sclerosis [7], the risk of MS increases 32-fold following infection with EBV [8].  
71 Human herpesvirus 6A (HHV-6A) has been associated with a higher risk of developing  
72 multiple sclerosis. Cytomegalovirus (CMV) infection may be associated with the  
73 occurrence of aquaporin-4 antibody-positive NMO spectrum disorder (AQP4 IgG+  
74 NMOSD) [9]. CMV and EBV are also frequently identified as antecedent pathogens of  
75 GBS [10]. Case reports of CIDP have found associations with CMV and EBV [11].

76 The association between EBV infection and the pathogenesis of MG remains  
77 controversial [12, 13]. Meanwhile, the associations between viruses of the Herpesviridae  
78 family and MG remain unclear. Existing observational studies and case reports have  
79 limited sample sizes, which reduces the statistical power to detect true associations and  
80 increases the likelihood of random error. In addition, it is difficult to draw causal  
81 conclusions from observational evidence due to residual confounding and reverse  
82 causation [14].

83 Mendelian randomisation (MR) is a novel approach that may offer more effective  
84 solutions to the above shortcomings. MR uses genetic variations that affect exposure as  
85 instrumental variables (IVs) to assess the causal relationship between exposure and  
86 outcomes. Because alleles are randomly assigned at conception, they are unaffected by  
87 confounding factors and disease states. By using genetic variants as IVs, MR can reduce

88 the confounding effects of environmental factors and avoid reverse causation bias [15,  
89 16].

90 Previous MR studies have found no association between herpes simplex virus (HSV)  
91 infection and MS [17], whereas varicella infection is associated with MS [18]. Compared  
92 to viral infections, antibody immune responses may not only serve as markers of infection  
93 exposure, but also potentially provide clues to the pathophysiological mechanisms  
94 associated with ANDs. However, whether there is a causal relationship between these  
95 common herpesvirus-induced antibody immune responses and ANDs is unknown, and to  
96 the best of our knowledge, our study will be the first to investigate the causal relationship  
97 between herpesvirus antibodies and ANDs, thereby further exploring new potential  
98 therapeutic targets and potentially informing vaccine selection for patients with ANDs.

## 99 **Materials and Methods**

### 100 **Study Design**

101 MR analysis is a statistical technique used to identify causal relationships,  
102 particularly within observational data. It uses genetic variants that influence exposure as  
103 instrumental variables (IVs) to assess the causal relationship between exposure and  
104 outcomes. A key advantage of MR analysis is its ability to mitigate bias arising from  
105 confounding and reverse causation, as genetic variations are generally not influenced by  
106 environmental or behavioural factors [15, 16]. MR studies will help to overcome current  
107 obstacles in investigating the relationship between antibody immune responses following  
108 herpesvirus infection and various ANDs, thus facilitating a more accurate investigation of  
109 direct causal relationships.

## 110 **Data Source**

111 Our study investigated the immune response of 22 antibodies to five types of  
112 herpesvirus infection: Anti-CMV IgG seropositivity, CMV pp28 antibody levels, CMV pp52  
113 antibody levels, CMV pp150 antibody levels; Anti-EBV IgG seropositivity, EBV early  
114 antigen-D (EA-D) antibody levels, EBV encoded nuclear antigen-1 (EBNA-1) antibody  
115 levels, EBV viral capsid antigen (VCA) p18 antibody levels, EBV ZEBRA antibody levels;  
116 Anti-HHV6 IgG seropositivity, Anti-HHV6 IE1A IgG seropositivity, HHV6 IE1A antibody  
117 level, Anti-HHV6 IE1B IgG seropositivity, HHV6 IE1B antibody level, HHV6 p101k  
118 antibody level, Anti-HHV7 IgG seropositivity, HHV7 U14 antibody levels, Anti-HSV1 IgG  
119 seropositivity, HSV1 mgG-1 antibody levels, Anti-HSV2 IgG seropositivity, HSV2 mgG-1  
120 antibody levels; Varicella zoster virus glycoprotein E and I (VZV gE and gI) antibody  
121 levels.

122 The above immune responses were investigated in a Genome-Wide Association  
123 Study (GWAS) involving a total of 8,735 individuals for case-control phenotypes and an  
124 average (range) of 4,286 (276-8,555) samples per quantitative analysis [19].

125 Genome-wide summary data for MS consisting of 47,429 cases and 68,374 controls  
126 from the European population were obtained from the International MS Genetics  
127 Consortium (IMSGC) [20]. To further validate the positive results, UK Biobank (1679  
128 cases and 461254 controls, <https://gwas.mrcieu.ac.uk/datasets/ukb-b-17670/>) and  
129 FinnGen (2620 cases and 449770 controls, [https://r11.finngen.fi/pheno/G6\\_MS](https://r11.finngen.fi/pheno/G6_MS)) for MS  
130 were used.

131 NMO-related GWAS data were obtained from the largest and most recent NMO

132 GWAS meta-analysis, which included 215 NMO cases and 1,244 controls [21].

133 The largest MG GWAS reported by Chia et al. was used for the primary analysis in  
134 this study, which included 1,873 cases and 36,370 controls [22]  
135 (<https://www.ebi.ac.uk/gwas/>). The MG GWAS focused only on cases positive for anti-  
136 acetylcholine receptor antibodies (anti-AChR), excluding individuals positive for  
137 antibodies to muscle-specific kinase (anti-MuSK). For external validation, summary  
138 statistics were obtained from the UK Biobank (224 cases and 417332 controls,  
139 <http://www.nealelab.is/uk-biobank>) and the FinnGen (504 cases and 449570 controls,  
140 [https://r11.finnngen.fi/pheno/G6\\_MYASTHENIA](https://r11.finnngen.fi/pheno/G6_MYASTHENIA)).

141 For GBS, data were obtained from the FinnGen Biobank with 489 cases and 445865  
142 controls ([https://r11.finnngen.fi/pheno/G6\\_GUILBAR](https://r11.finnngen.fi/pheno/G6_GUILBAR)). Genetic associations for CIDP were  
143 derived from 456,348 individuals of European ancestry from the UK Biobank using a fast  
144 genome-wide association generalised linear mixed model and were obtained from the  
145 catalogue [23]. Detailed information of Data used in our study was shown in  
146 supplementary table 1.

## 147 **Instrumental Variable Selection**

148 We screened single nucleotide polymorphisms (SNPs) that showed a significant  
149 association with exposure factors in the exposure GWAS ( $P < 5 \times 10^{-8}$ ). When the  
150 number of SNPs was less than 10, we relaxed the SNPs selection criterion to a p-value  
151 threshold of  $p < 1e-07$  or  $p < 1e-06$ , with a minimum standard of  $p < 1e-05$  [24]. SNPs with  
152 minor allele frequencies (MAF  $< 0.01$ ) were also deleted, and linkage disequilibrium (LD)  
153 between SNPs was resolved by clustering ( $R^2 < 0.001$  within a 10 Mkb clustering

154 distance). Palindromic SNPs were removed. The exposure and outcome data sets were  
155 then harmonised. The proportion of variance explained by instrumental variables was  
156 calculated using the formula:  $R^2 = 2 \times \beta^2 \times EAF \times (1 - EAF) / (2 \times \beta^2 \times EAF \times (1 - EAF) +$   
157  $2 \times SE^2 \times N \times EAF \times (1 - EAF))$ , where N is the sample size [25]. The power of the  
158 genetic instrument was assessed using the F-statistic, calculated as  $F = R^2 \times (N - 2) / (1 -$   
159  $R^2)$ . An F-statistic greater than 10 indicates a strong instrument, IVs with F-statistics less  
160 than 10 were considered weak and thus excluded from the analysis. The  
161 SNiPA(<https://snipa.org/snipa3/>) and GWAS catalogue(<https://www.ebi.ac.uk/gwas/home>)  
162 was used to check that the SNPs were not associated with other relevant confounders,  
163 such as smoking, body mass index (BMI), physical activity, serum 25-hydroxyvitamin D  
164 levels.

## 165 **Mendelian Randomization Analysis**

166 When there was only one IV, the Wald ratio method was utilized. In cases where two  
167 IVs were present, Inverse Variance Weighted (IVW) method will be used. With more than  
168 two instrumental variables (IVs) available, univariable Two-Sample MR (TSMR) was  
169 used to estimate the total causal effects of antibody immune response on ANDs, we  
170 applied five MR analysis methods: IVW, MR Egger, Weighted Median, Simple Mode, and  
171 Weighted Mode, IVW served as the primary approach for result interpretation [26].

172 To clarify whether there were reverse causal relationships between ANDs and  
173 antibody immune responses, we also conducted reverse Mendelian randomization.

174 To account for multiple comparisons, the Bonferroni correction was utilized. We set a  
175 significance threshold of  $\alpha = 0.05/n$  (where n represents the number of comparisons) to



176 mitigate the increased risk of false positives from multiple testing [27]. This correction  
177 method helps maintain the overall Type I error rate at an acceptable level while  
178 controlling for the familywise error rate. Therefore, a P-value below 4.55E-04 (calculated  
179 as 0.05 divided by the product of 22 comparisons and 5 outcomes) was considered  
180 statistically significant.

181 MR Egger intercept test and Outlier (MR-PRESSO) were used to detect the  
182 presence of pleiotropy, When the P-values for MR Egger intercept and MR-PRESSO are  
183 less than or equal to 0.05, it suggests the presence of pleiotropic IVs. To address this, we  
184 iteratively performed MR Egger intercept and MR-PRESSO tests, removing any outliers  
185 each time, until no horizontal pleiotropy was detected. Furthermore, we also employed  
186 visual inspection of the scatter plot and forest plot to test the MR “no horizontal  
187 pleiotropy”. Additionally, Cochran’s Q statistic was used to assess the degree of  
188 heterogeneity among all IVs. P-value from the Q-test greater than 0.05 indicates that  
189 there is no significant heterogeneity among the IVs.

190 To assess the robustness of the identified causal associations, we conducted two  
191 sensitivity analyses: the MR-Egger intercept test and leave-one-out analysis. The  
192 intercept from the MR-Egger test estimates the degree of directional pleiotropy, while the  
193 leave-one-out analysis determines if the significant results are influenced by any single  
194 SNP.

## 195 **Meta-analysis**

196 For MS and MG, when the MR results of the discovery and replication phases were  
197 inconsistent, the meta-analysis was performed to assess combined causality. The choice

198 of effect model was based on the heterogeneity of the results. If there was little significant  
199 heterogeneity with  $I^2 \leq 50\%$ , the fixed-effects model was used to combine the results.  
200 Otherwise, the random effects model was used.

201 The statistical analyses in this study were performed using R version 4.4.1, including  
202 TwoSampleMR, MRPRESSO and Metafor. The study protocol and details were not pre-  
203 registered

## 204 **Results**


### 205 **Selection of Instrumental Variables**

206 Detailed information on the IVs of antibody immune responses to five types of  
207 herpesvirus is shown in Supplementary Table 2. The P value thresholds for anti-CMV  
208 IgG seropositivity, CMV pp28 antibody levels, CMV pp52 antibody levels , CMV pp150  
209 antibody levels, anti-EBV IgG seropositivity, anti-HHV6 IgG seropositivity, anti-HHV6  
210 IE1A IgG seropositivity, HHV6 IE1A antibody levels, anti-HHV6 IE1B IgG seropositivity,  
211 HHV6 IE1B antibody levels, HPV6 p101k antibody levels, anti-HHV7 IgG seropositivity,  
212 anti-HSV 1 IgG seropositivity, HSV1 mgG-1 antibody levels anti-HSV2 IgG seropositivity  
213 and HSV2 mgG-1 antibody levels were  $1e-05$  , HHV7 U14 antibody levels were  $1e-07$ ,  
214 EBV EA-D antibody levels, EBV EBNA-1 antibody levels, EBV VCA p18 antibody levels,  
215 EBV ZEBRA antibody levels and VZV gE and gI antibody levels were  $5e-08$ . rs1808192  
216 in HHV7 U14 antibody levels, rs34811474 in anti-HSV 1 IgG seropositivity and  
217 rs13204572 in VZV gE and gI antibody levels were deleted as they were associated with  
218 BMI. IVs for MS, NMO, MG, CIDP, GBS are shown in Supplementary Tables 3, 5, 7, 9,  
219 11, respectively. All F values of the IVs were greater than 10, indicating that weak

220 instruments were excluded.

## 221 **Antibody Immune Response Following Herpesvirus** 222 **Infection on MS**

223 In this study, the antibody unit was the logarithmic transformation of the antibody median  
224 fluorescence intensity. We observed a causal effect of a 1-unit increase in EBV EBNA-1  
225 antibody levels, EBV VCA p18 antibody levels and HHV7 U14 antibody levels correlating  
226 with an increasing risk of MS [IVW: odds ratio (OR) = 3.009, 95% CI: 2.377-3.807,  
227  $P=4.772e-20$ , adjusted  $p=2.250e-18$ ; IVW: OR=8.700, 95% CI: 6.128-12.351,  $P=1.059e-$   
228 33, adjusted  $p=1.165e-31$  and IVW: OR=3.359, 95%CI: 2.034-5.546,  $P=2.187e-06$ ,  
229 adjusted  $p=2.406e-04$ ]. In addition, causal evidence was also found for a differential  
230 effect of a 1-unit increase in EBV ZEBRA antibody levels (IVW: OR = 0.592, 95% CI:  
231 0.491-0.713,  $P = 3.195e-08$ , adjusted  $p = 3.515e-6$ ), the analysis did not reveal causal  
232 relationships between other antibodies and the risk of MS (Fig 1, S Table 4). To validate  
233 the above results, we also used the UK Biobank and FinnGen MS datasets, with detailed  
234 results shown in Table 1. In all three datasets, the causal effects of EBV EBNA antibody  
235 levels and EBV VCA p18 antibody levels on MS were significant; however, the MR  
236 results of HHV7 U14 antibody levels and EBV ZEBRA antibody levels on MS differed  
237 between the three datasets, and the meta-analysis did not confirm that the overall effects  
238 of these on MS were significant.



239

240 **Fig 1** : MR estimate results of antibodies of five herpesviridae viruses on MS.

241 **Table 1.** Mendelian Randomization Analysis of the Causal Effects of Herpesvirus Antibodies on

242 Multiple Sclerosis Risk Across Different Datasets

Exposure	Outcome	datasets	Method	OR (95%CI)	P	Adjusted P
EBV EBNA-1 antibody levels	MS	IMSGC	IVW	3.009(2.377-3.807)	4.772e-20	2.250e-18
		UK Biobank	IVW	1.004(1.003-1.005)	3.722e-27	/
		FinnGen	IVW	1.885(1.342-2.648)	2.534e-04	/
EBV VCA p18 antibody levels	MS	IMSGC	IVW	8.700(6.128-12.351)	1.059e-33	1.165e-31
		UK Biobank	IVW	1.008(1.006-1.009)	2.275e-24	/
		FinnGen	IVW	6.888(4.725-10.041)	1.060e-23	/
HHV7 U14 antibody levels	MS	IMSGC	IVW	3.359 (2.034-5.546)	2.187e-06	2.406e-04
		UK Biobank	IVW	0.100(0.998-1.002)	0.824	/
		FinnGen	IVW	1.208(0.802-1.820)	0.366	/
		Toal	REMA	1.647 (0.871-3.114)	0.234	/
Heterogeneity: $I^2=93.38\%$ , $\tau^2=0.369$ , $P<0.05$						
EBV ZEBRA antibody levels	MS	IMSGC	IVW	0.592(0.491–0.713)	3.195e-08	3.515e-6
		UK Biobank	IVW	0.997(0.996-0.998)	3.589e-13	/

FinnGen	IVW	0.876(0.667-1.151)	0.343	/
Toal	REMA	0.807(0.587 -1.109)	0.125	/
Heterogeneity: $I^2=91.96\%$ , $\tau^2=0.070$ , $P< 0.05$				

243 **Abbreviations:** MS: multiple sclerosis; EBV: Epstein-Barr virus; HHV: human herpes virus; IVW: IVW: inverse  
244 variance weighted; REMA: Random Effects Meta-Analysis.

## 245 **Pleiotropy and Sensitivity Analysis for MS**

246 Heterogeneity was observed among the IVs of EBV EBNA-1 antibody levels  
247 ( $Q=27.055$   $P=1.414e-4$ ), EBV VCA p18 antibody levels ( $Q=70.545$   $P=1.147e-12$ ), HHV6  
248 IE1A antibody levels ( $Q=17.036$   $P=0.048$ ) and anti-HSV2 IgG seropositivity ( $Q=13.885$   
249  $P=0.031$ ) in terms of their effect on MS (S Table 4). All p-values from the MR Egger  
250 intercepts and MR-PRESSO global tests were greater than 0.05, indicating the absence  
251 of outlier SNPs and no evidence of horizontal pleiotropy between the IVs and outcomes.  
252 Leave-one-out analysis showed that the results remained consistent regardless of which  
253 individual SNP was excluded (S Fig 1-22).

254 It is noteworthy that the final IVs of HHV7 U14 antibody levels and Varicella zoster  
255 virus glycoproteins E and I (VZV gE and gI) antibody levels, filtered by the above steps,  
256 consist of only two SNPs. IVs of the former have no heterogeneity ( $Q=2.823$   $P=0.093$ ),  
257 single SNP MR analysis showed the similar result (rs7773105:  $P=2.175e-05$ , adjusted  
258  $P=0.002$ , OR=2.562, 95%CI:1.660-3.956; rs805282:  $P=3.911e-12$ , adjusted  $P=4.300e-11$ ,  
259 OR=4.277, 95%CI: 2.97-6.448), we consider the causal relationship between HHV7 U14  
260 antibody levels and MS to be reliable. However, there was significant heterogeneity  
261 between these two IVs of VZV gE and gI antibody levels ( $Q= 53.561$   $P= 2.507e-13$ ). In  
262 the single SNP MR analysis, the significance of the effects of these two IVs on MS varied

263 (rs9270551:  $P = 2.78E-276$ , adjusted  $P = 3.058e-274$ , OR =  $0.557e-06$ , 95% CI:  $0.369e-$   
264  $03 - 0.843e-03$ ; rs9272285:  $P = 1.052E-03$ , adjusted  $P = 0.116$ , OR =  $0.106$ , 95% CI:  
265  $0.028-0.406$ ). In particular, rs9270551 was strongly associated with MS ( $P = 1E-200$ ),  
266 suggesting the presence of horizontal pleiotropy. Therefore, based on the MISGC  
267 databases, we used rs9272285 as an IV for VZV gE and gl antibody levels for MS. To  
268 further investigate the association between VZV gE and gl antibody levels and MS, we  
269 also performed MR analysis based on the MS datasets in UK Biobank and FinnGen with  
270 the following results: OR (95%CI) = $1.000(0.999-1.001)$ ,  $P=0.299$  (UK Biobank),  
271  $0.2171830962485$  OR (95%CI) = $0.820 (0.5978-1.124)$   $P=0.217$  (FinnGen), so there  
272 wasn't the causal relationship between VZV gE and gl antibody levels and MS.


## 273 **MS on Antibody Immune Response**

274 Reverse Mendelian randomization revealed that MS does not have significant  
275 reverse causal effects on antibodies to the aforementioned herpesvirus antigens, with all  
276 p-values greater than the adjusted p-value ( $4.550e-04$ ) (S Fig 23).

## 277 **Antibody Immune Response on NMO**

278 There is a causal relationship between elevated levels of two EBV-related antibodies  
279 and a reduced risk of NMO. These two antibodies are EBV EA-D antibody levels (IVW:  
280 OR =  $0.043$  95% CI:  $0.010-0.196$ ,  $P = 4.546e-05$ , adjusted  $p=0.005$ ) and EBV ZEBRA  
281 antibody levels (IVW: OR =  $0.079$ , 95% CI:  $0.043-0.147$ ,  $P = 7.587e-16$ , adjusted  $p=8.$   
282  $345e-14$ ). Conversely, an increased risk of NMO could be caused by higher antibody  
283 levels of HHV7 U14 (IVW: OR = $10.641$  95% CI:  $3.025-37.429$ ,  $P=2.285e-04$  adjusted  
284  $p=0.025$ ) or VZV gE and gl (IVW: OR = $17.220$  95% CI:  $9.760-30.380$ ,  $P=8.727e-23$

285 adjusted  $p=9.599e-21$ ). Antibodies to other viruses of the Herpesviridae family had no  
 286 causal effect on the risk of NMO (Fig 2, S Table 6).



287

288 Fig 2 MR estimate results of antibodies of five herpesviridae viruses on NMO.

## 289 Pleiotropy and Sensitivity Analysis for NMO

290 Heterogeneity was observed in the IVs for EBV EA-D antibody levels ( $Q=6.892$ ,  
 291  $P=0.075$ ), EBV EBNA-1 antibody levels ( $Q=70.545$ ,  $P=6.776e-4$ ), EBV ZEBRA antibody  
 292 levels ( $Q=34.471$ ,  $P=0.011$ ), HHV6 IE1A antibody levels ( $Q=29.584$ ,  $P=0.042$ ) and  
 293 HHV6 IE1B antibody levels ( $Q=31.661$ ,  $P=0.034$ ) on NMO (Supplementary Table 6). The  
 294 MR-PRESSO global test indicated the presence of horizontal pleiotropy between the IVs  
 295 for EBV EBNA-1 antibody levels on NMO ( $P=0.001$ ), EBV ZEBRA antibody levels  
 296 ( $P=0.022$ ) and HHV6 IE1B antibody levels ( $P=0.034$ ). However, the p-values of the  
 297 Egger intercept were greater than 0.05 and no significant outliers were detected. The  
 298 leave-one-out analysis confirmed that no single SNP significantly altered the overall

299 results. Therefore, the results still have some informative value.

300 For the IVs of EBV ZEBRA antibody levels, the p-value of the MR-PRESSO global  
301 test was less than 0.05, but the Egger intercept was greater than 0.05. All five MR  
302 statistical methods showed a consistent direction of effect, similar effect estimates and  
303 OR values (Supplementary Table 6). The leave-one-out analysis again showed that the  
304 results were robust to the exclusion of any single SNP (Supplementary Fig 9). Thus, the  
305 overall results continue to support the existence of a causal relationship between EBV  
306 ZEBRA antibody levels and NMO.

307 Pleiotropy tests for the IVs of other antibodies showed no outlier SNPs and no  
308 evidence of horizontal pleiotropy between them and the outcomes (Supplementary Table  
309 6). Leave-one-out analysis consistently showed that excluding any single SNP did not  
310 affect the results (S Fig 1-22).


### 311 **NMO on Antibody Immune Response**

312 Reverse causal effects of NMO on antibodies were not found (S Fig 24).

### 313 **Antibody Immune Response on MG**

314 We found a causal effect between increased VZV gE and gI antibody levels and an  
315 increased risk of MG (IVW: OR = 2.542 95% CI: 1.972-3.277, P =5.897e-13 adjusted p=  
316 2.594e-12). No significant associations were found between other antibodies and MG  
317 (Fig 3). In addition, the UK Biobank and FinnGen MG datasets were used to validate this  
318 result, with detailed results shown in Table 2. In all three datasets, the causal effect of  
319 VZV gE and gI antibody levels on MG was all significant.





320

321 **Fig 3** MR estimate results of antibodies of five herpesviridae viruses on MG.

322 **Table 2.** MR estimate results of antibodies of VZV gE and gI antibody levels on MG.

Exposure	Outcome	Author and datasets	Method	OR (95%CI)	P	Adjusted P
VZV gE and gI antibody levels	MG	Jiang L et al.	IVW	2.542(1.972-3.277)	5.897e-13	2.594e-12
		UK Biobank	IVW	1.00024(1.000035-1.000445)	0.022	/
		FinnGen	IVW	2.619(1.768-3.880)	1.576e-06	/

323 **Abbreviations:** MG: myasthenia gravi; VZV: varicella zoster virus; IVW: inverse variance

324 weighted; REMA: random effects meta-Analysis.

### 325 Pleiotropy and Sensitivity Analysis for MG

326 IVs of EBV EA-D antibody levels (Q=44.715, P=0.004) and EBV ZEBRA antibody

327 levels (Q=37.615, P=0.004) show significant heterogeneity (Supplementary Table 8).

328 Although MR-PRESSO identified pleiotropy, the Egger intercept did not indicate


329 significant pleiotropy and no significant outliers were detected. IVs from other antibodies  
330 did not show heterogeneity and pleiotropy (S Table 8). The leave-one-out analysis gave  
331 similar results, even after excluding individual SNPs (S Fig 1-22).

## 332 **MG on Antibody Immune Responses**

333 The adjusted P values from the MR analysis indicated that there was no causal  
334 relationship between MG and any of the 22 types of antibody immune response (S Fig  
335 24).


## 336 **Causal Relationships Detected Between Antibody** 337 **Immune Responses and GBS/CIDP**

338 We found no forward or reverse causal relationships between the 22 antibody  
339 immune responses to five types of herpesviruses and GBS and CIDP (Fig 4-5 ; S Fig 26-  
340 27). IVs for HSV1 mgG-1 antibody levels on CIDP showed heterogeneity ( $Q = 44.905$ ,  $P$   
341  $= 0.03$ ) ( S Table 12 ) . Pleiotropy was detected by MR-PRESSO but not by the Egger  
342 intercept, and the MR-PRESSO global test did not identify any significant outliers. Leave-  
343 one-out analysis showed no significant differences in MR results after removing individual  
344 SNPs (S Fig 1-22).



345

346 Fig 4 MR estimate results of antibodies of five herpesviridae viruses on GBS.



347

348 Fig 5 MR estimate results of antibodies of five herpesviridae viruses on CIDP.

349 All other results, including those for GBS and CIDP, passed the heterogeneity and  
350 pleiotropy tests. The sensitivity analysis did not identify any SNPs that significantly  
351 affected the overall results.

## 352 **Dicussion**

353 As the MR results showed, EBV EBNA-1 antibody and VCA p18 antibody were  
354 positively correlated with MS. Levels of EBV ZEBRA antibody were negatively correlated  
355 with MS in the IMSGC and UK Biobank datasets, but not in FinnGen, and the meta-  
356 analyses did not confirm a causal relationship. In addition, HHV7 U14 antibody levels  
357 were positively associated with MS in the IMSGC dataset, but not in the UK Biobank or  
358 FinnGen datasets, and the overall causal relationship was not established by the meta-  
359 analyses.

360 Negative associations between EBV ZEBRA and EA-D antibody levels and NMO  
361 were shown in this study. Conversely, a positive association was found between NMO  
362 and antibody levels of VZV gE, VZV gI and HHV7 U14. VZV gE and gI antibody levels  
363 showed a positive association with MG.

364 The above results suggest an important role for EBV antigen-associated antibodies in  
365 the pathogenesis of AND. EBV infects and persists in human B cells by exploiting the B  
366 cell environment to sustain its life cycle while evading the host immune system through  
367 minimal expression of viral proteins [28]. Several antibodies to EBV proteins can be  
368 detected in EBV carriers. These proteins include EBNA-1 (BKRF1), a latency protein;  
369 VCA p18 (BFRF3), a structural protein of the mature virus; ZEBRA (BZLF1), a lytic cycle  
370 protein; and EA-D, a basic component of the viral DNA replication complex. [28, 29].

371 Previous studies have confirmed that higher antibody levels against EBNA-1 and VCA  
372 p18 (or VCA) are associated with an increased risk of MS; in individuals with genetic  
373 factors associated with lower EBNA-1 IgG titres, the onset of MS was delayed by 3.5  
374 years [30, 31], [32]. A region within the carboxyl half of EBNA1 (amino acids 385-420)  
375 induces elevated antibody levels in MS patients and shows the strongest association with  
376 MS risk compared to antibody levels against other domains of EBNA1 [33]. EBNA1-  
377 specific antibodies are found in the cerebrospinal fluid (CSF) of some MS patients; these  
378 antibodies may play a role in the formation of oligoclonal bands, which are antibodies  
379 produced by clonal B-cell-derived plasma cells in the central nervous system and are a  
380 hallmark of MS [34]. Injection of a peptide derived from the aa395-420 region of EBNA1  
381 into mice with experimental autoimmune encephalomyelitis (EAE) exacerbated CNS  
382 autoimmunity [34, 35].

383 Our research confirms a causal relationship between antibodies to EBNA-1 or VCA p18  
384 and MS. However, the exact mechanisms by which these two antibodies cause MS are  
385 not yet clear. Based on the current evidence , molecular mimicry of EBNA-1 and VCA  
386 p18 may play some role. Antibodies against VCA p18 (BFRF3) cross-react with the  
387 cytoplasmic protein septin-9 [36]. Septin-9, a cytoplasmic protein that forms filaments,  
388 may play a role in cytokinesis, exocytosis, neurite outgrowth and cell cycle control. While  
389 it is widely expressed in various tissues, it is emerging as an intriguing candidate  
390 autoantigen for MS due to gene mutations that cause hereditary neuralgic amyotrophy  
391 [37]. In the CNS, septin-9 is mainly found in neurons and its expression is upregulated  
392 after trauma [38]. Antibodies to EBNA1 have been observed to cross-react with

393 anoctamin 2,  $\alpha$ B-crystallin, myelin basic protein (MBP) and glial cell adhesion molecule  
394 [33, 34, 39]. However, the pathogenic role of these antibodies remains unclear because  
395 successful cell-depleting therapy for MS does not affect antibody-producing plasma cells  
396 in the short term. Moreover, such treatment does not seem to reduce oligoclonal bands  
397 [7]. These two antibodies may become new therapeutic targets in MS, particularly in  
398 patient groups with high levels of these antibodies and poor response to other treatments.

399 ZEBRA (BZLF1) was considered to be a major environmental factor associated with  
400 MS and a significant contributor to the disease process [40]. BZLF1 was found in 46% of  
401 MS brains, mainly associated with chronic lesions, and in 44% of non-MS brain tissue  
402 [41]. ZEBRA is recognised as one of the viral immediate early genes that play an  
403 important role in the transition of EBV from latency to lytic replication [42], Reactivation of  
404 latent EBV infection is associated with disease activity in MS patients; however, research  
405 results are controversial [43-45]. Meanwhile, increasing EBV ZEBRA antibodies have not  
406 been found in MS [46], the role of ZEBRA antibodies in MS remains unclear.

407 Previous research found that anti-EA seropositivity was significantly higher in the  
408 NMOSD group compared to the HC group and MS patients [47, 48], but another study  
409 suggested that exposure to Epstein-Barr virus was not associated with an increased  
410 likelihood of NMO compared to healthy subjects [49]. Although our research suggests  
411 that BV ZEBRA and EA-D antibody levels may be associated with a reduced risk of NMO,  
412 further studies are needed to confirm this. Based on the advantages of MR statistics, this  
413 study suggests that EBV antibodies may provide new clues for NMO treatment. In  
414 particular, for NMO patients with high levels of EBV antibodies, understanding the

415 different roles of different antibodies in the pathogenesis of NMO may facilitate the  
416 exploration of personalised treatment approaches.

417 Current research on the association between HHV infection and the risk of MS has  
418 yielded controversial results, [50-52], This controversy is reflected in the results of this  
419 MR analysis. A meta-analysis found that CMV IgG seroprevalence was lower in people  
420 with MS than in controls in Europe [53]. However, our study does not support a causal  
421 relationship between CMV antibody immune response and risk of MS. Although one MR  
422 study suggested a causal relationship between herpesvirus infection and MS, we did not  
423 find a causal relationship between VZV gE and gI antibody levels and MS [18].

424 At present, the relationship between HHV and NMO is not very clear. Our study  
425 suggests that HHV may be one of the important pathogens of NMO, and HHV 7 U14  
426 antibody may be detrimental to NMO, but its exact pathogenic role in NMO requires  
427 further investigation. VZV has been considered as a precursor infectious agent of NMO  
428 [54-56], Causal association between chickenpox infection and NMO was also recently  
429 confirmed by MR study [57], Our study further confirmed a causal effect of VZV gE and gI  
430 antibody levels on NMO. VZV infection is an important risk factor for NMO, and  
431 vaccination against VZV may help to reduce the risk of NMO. For NMO patients with high  
432 levels of VZV gE and gI antibodies, the immune response and related pathogenic  
433 mechanisms induced by VZV infection could potentially become a new therapeutic  
434 approach.

435 Among 22 types of antibody immune response, only VZV gE and gI antibody levels  
436 were found to be associated with MG. The resultant GWAS data from two different

437 datasets both confirm this causal association, suggesting that unlike in MS, the  
438 pathogenic role of VZV in MG was robust, which may imply new therapeutic targets for  
439 MG, especially for patients with high levels of this antibody.

440 This study has a number of important strengths. First, we effectively reduced the  
441 influence of confounding factors and improved the accuracy and reliability of our results  
442 by using a novel MR analysis method. Second, our comprehensive analysis explored the  
443 causal relationships between 22 antibody immune responses to five herpesvirus  
444 infections and five types of ANDs. This provided a detailed understanding of their  
445 interactions. Third, we applied a rigorous correction procedure to ensure the robustness  
446 and validity of our findings. For positive results, we cross-validated with additional  
447 publicly available GWAS outcome data. We also conducted further meta-analyses to  
448 resolve any inconsistencies. These measures helped to reduce the risk of false positives.  
449 They also strengthened the credibility of our conclusions.

450 Although this study provides valuable insights, it has several limitations that should  
451 be acknowledged. First, the use of summary level data in MR analyses, although  
452 powerful, may introduce bias due to the assumption of linearity and the inability to  
453 explore non-linear relationships. In addition, the generalisability of the findings is limited  
454 by the demographic and genetic composition of the datasets used, which are  
455 predominantly of European ancestry. This raises questions about the applicability of the  
456 results to more diverse populations. Another limitation is the potential for pleiotropy,  
457 where genetic variants used as instruments may affect the outcome through pathways  
458 other than the exposure of interest, leading to biased estimates. Although we used



459 methods to mitigate pleiotropy, such as MR-PRESSO, the possibility of residual  
460 confounding cannot be completely excluded. Finally, the study relies on the availability  
461 and quality of existing GWAS datasets, which may vary in their coverage and accuracy of  
462 antibody measurements, potentially affecting the robustness of the findings. Future  
463 studies should aim to validate these findings in more diverse populations and with  
464 individual-level data to better understand the complex relationships between herpesvirus  
465 antibodies and autoimmune neurodegenerative diseases.

## 466 **Conclusion**

467 The results of this study reveal predicted causal effects of EBV EBNA-1 antibody, EBV  
468 VCA p18 antibody on MS, HHV7 U14, VZV gE and gI antibody, EBV EA-D antibody and  
469 EBV ZEBRA antibody on NMO, VZV gE and gI antibody on MG, This might suggest  
470 potential role for above antibodies in the pathogenesis of ANDs, also This finding  
471 highlights the need for further exploration into the specific mechanisms of above  
472 antibodies in the pathophysiological processes of ANDs, providing an important  
473 theoretical basis for the development of more effective treatment strategies in the future.

474

## 475 **Declarations**

### 476 **Ethics approval and consent to participate**

477 Publicly available datasets were used for all data in our study. Informed consent was  
478 obtained from all participants prior to enrollment, and ethical approval was obtained for  
479 each cohort.

480

## 481 **Consent for Publication**

482 All authors provide their consent for the publication of this manuscript.

483

## 484 **Availability of data and materials**

485 The original papers presented in this study can be found in the supplementary materials.

486

## 487 **Competing Interests**

488 The authors declare that they have no competing interests. The research, data  
489 interpretation, and conclusions presented in this manuscript were not influenced by any  
490 financial, personal, or professional conflicts.

491

## 492 **Funding**

493 Grant from Science and Technology Program of Guangzhou : Key Lab of Guangzhou  
494 Basic and Translational Research of Pan-vascular Diseases ( 202201020042 ) ; Youth  
495 Pre-employment Training Programme Research Fund ( 2023ZC07 ) ; Natural Science  
496 Foundation of Hunan Province - Regional Joint Fund ( 2024JJ7012).

497

## 498 **Authors' contributions**

499 Sunjun Sun: Writing – original draft, Visualization, Validation, Methodology, Formal  
500 analysis, Funding acquisition;

501 Yiyong Wen: Writing- original draft, Formal analysis, review & editing;

502 Pan Tang: Writing– review & editing, Validation.

503 Fan Xie: Writing – review & editing, Visualization, Validation.

504 Jun Wen: Writing – review & editing, Supervision,

505 Anding Xu: Writing –Conceptualization, review & editing, Supervision, Funding

506 acquisition. Project administration.

## 507 **Acknowledgements**

508 The authors thank the Multiple Sclerosis Genetics Consortium and the International

509 Myasthenia Gravis Genomics Consortium, the UK Biobank and the FinnGen study for

510 providing publicly available MS, MG and GBS GWAS summary statistics for this analysis ,

511 as well as the studies by Butler-Laporte G et al, Estrada K et al, Chia R et al, Jiang L et al

512 for antibody immune responses to five types of herpesvirus, NMO, MG, CIDP GWAS

513 summary statistics.

514

## 515 **List of abbreviations**

516 ANDs: Autoimmune neuroinflammatory diseases , MS: multiple sclerosis, NMO:

517 neuromyelitis optica, GBS: Guillain-Barr é syndrome, CIDP: chronic inflammatory

518 demyelinating polyneuropathy, MG: myasthenia gravis. CNS: central nervous system,

519 PNS: peripheral nervous system, NJM: neuromuscular junction. EBV: Epstein-Barr virus;

520 HHV 6A: Human herpesvirus 6A; CMV: Cytomegalovirus; AQP4 IgG+ NMOSD:

521 aquaporin-4 antibody-positive NMO spectrum disord , MR: mendelian randomisation ,

522 HSV: herpes simplex virus , EBNA-1: EBV encoded nuclear antigen-1 , EBV-VCA p18:

523 EBV viral capsid antigen p18,VZV gE and gI: Varicella zoster virus glycoprotein E and I ,

524 GWAS: Genome-Wide Association Study; IMSGC: International MS Genetics

525 Consortium; anti-AChR: anti-acetylcholine receptor antibodies; anti-MuSK: antibodies to  
526 muscle-specific kinase; SNPs: single nucleotide polymorphisms; MAF: minor allele  
527 frequencies; LD: linkage disequilibrium; BMI: body mass index; IVW: Inverse Variance  
528 Weight; IVs: instrumental variables (IVs); TSMR: Two-Sample MR; MR-PRESSO: MR  
529 Egger intercept test and Outlier; OR: odds ratio; CSF: cerebrospinal fluid; EAE:  
530 experimental autoimmune encephalomyelitis.

## 531 **References**

- 532 1. Khan AW, Farooq M, Hwang MJ, Haseeb M, Choi S. Autoimmune Neuroinflammatory  
533 Diseases: Role of Interleukins. *Int J Mol Sci.* 2023;24(9). Epub 20230427. doi:  
534 10.3390/ijms24097960. PubMed PMID: 37175665; PubMed Central PMCID:  
535 PMCPMC10178921.
- 536 2. Bhagavati S. Autoimmune Disorders of the Nervous System: Pathophysiology, Clinical  
537 Features, and Therapy. *Front Neurol.* 2021;12:664664. Epub 20210414. doi:  
538 10.3389/fneur.2021.664664. PubMed PMID: 33935958; PubMed Central PMCID:  
539 PMCPMC8079742.
- 540 3. Zarobkiewicz MK, Morawska I, Michalski A, Roliński J, Bojarska-Junak A. NKT and NKT-  
541 like Cells in Autoimmune Neuroinflammatory Diseases-Multiple Sclerosis, Myasthenia Gravis  
542 and Guillain-Barre Syndrome. *Int J Mol Sci.* 2021;22(17). Epub 20210901. doi:  
543 10.3390/ijms22179520. PubMed PMID: 34502425; PubMed Central PMCID:  
544 PMCPMC8431671.
- 545 4. Gogia B, Rocha Cabrero F, Khan Suheb MZ, Lui F, Rai PK. Chronic Inflammatory  
546 Demyelinating Polyradiculoneuropathy. *StatPearls. Treasure Island (FL): StatPearls*

547 Publishing

548 Copyright © 2024, StatPearls Publishing LLC.; 2024.

549 5. Miller FW. The increasing prevalence of autoimmunity and autoimmune diseases: an  
550 urgent call to action for improved understanding, diagnosis, treatment, and prevention. *Curr*  
551 *Opin Immunol.* 2023;80:102266. Epub 20221126. doi: 10.1016/j.coi.2022.102266. PubMed  
552 PMID: 36446151; PubMed Central PMCID: PMC9918670.

553 6. Pisetsky DS. Pathogenesis of autoimmune disease. *Nat Rev Nephrol.* 2023;19(8):509-24.  
554 Epub 20230510. doi: 10.1038/s41581-023-00720-1. PubMed PMID: 37165096; PubMed  
555 Central PMCID: PMC9918670.

556 7. Bjornevik K, Münz C, Cohen JL, Ascherio A. Epstein-Barr virus as a leading cause of  
557 multiple sclerosis: mechanisms and implications. *Nat Rev Neurol.* 2023;19(3):160-71. Epub  
558 20230209. doi: 10.1038/s41582-023-00775-5. PubMed PMID: 36759741.

559 8. Bjornevik K, Cortese M, Healy BC, Kuhle J, Mina MJ, Leng Y, et al. Longitudinal analysis  
560 reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science.*  
561 2022;375(6578):296-301. Epub 20220113. doi: 10.1126/science.abj8222. PubMed PMID:  
562 35025605.

563 9. Miao Y, Shi Z, Zhang W, Zhu L, Tang S, Chen H, et al. Immune Repertoire Profiling  
564 Reveals Its Clinical Application Potential and Triggers for Neuromyelitis Optica Spectrum  
565 Disorders. *Neurol Neuroimmunol Neuroinflamm.* 2023;10(5). Epub 20230706. doi:  
566 10.1212/nxi.0000000000200134. PubMed PMID: 37414573; PubMed Central PMCID:  
567 PMC9918670.

568 10. Kuwabara S. Guillain-Barré syndrome: epidemiology, pathophysiology and management.

- 569 Drugs. 2004;64(6):597-610. doi: 10.2165/00003495-200464060-00003. PubMed PMID:  
570 15018590.
- 571 11. Rodríguez Y, Vatti N, Ramírez-Santana C, Chang C, Mancera-Páez O, Gershwin ME,  
572 Anaya JM. Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease. J  
573 Autoimmun. 2019;102:8-37. Epub 20190506. doi: 10.1016/j.jaut.2019.04.021. PubMed PMID:  
574 31072742.
- 575 12. Kakalacheva K, Maurer MA, Tackenberg B, Münz C, Willcox N, Lü nemann JD.  
576 Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann  
577 Neurol. 2011;70(3):508-14. doi: 10.1002/ana.22488. PubMed PMID: 21905082.
- 578 13. Cavalcante P, Marcuzzo S, Franzi S, Galbardi B, Maggi L, Motta T, et al. Epstein-Barr  
579 virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an  
580 autoimmunity mediator? Oncotarget. 2017;8(56):95432-49. Epub 20170908. doi:  
581 10.18632/oncotarget.20731. PubMed PMID: 29221139; PubMed Central PMCID:  
582 PMCPMC5707033.
- 583 14. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian  
584 randomization: using genes as instruments for making causal inferences in epidemiology.  
585 Stat Med. 2008;27(8):1133-63. doi: 10.1002/sim.3034. PubMed PMID: 17886233.
- 586 15. Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to  
587 understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22. doi:  
588 10.1093/ije/dyg070. PubMed PMID: 12689998.
- 589 16. Zheng J, Baird D, Borges MC, Bowden J, Hemani G, Haycock P, et al. Recent  
590 Developments in Mendelian Randomization Studies. Curr Epidemiol Rep. 2017;4(4):330-45.

- 591 Epub 20171122. doi: 10.1007/s40471-017-0128-6. PubMed PMID: 29226067; PubMed  
592 Central PMCID: PMCPMC5711966.
- 593 17. Zhang W, Wu P, Yin R, Sun M, Zhang R, Liao X, et al. Mendelian Randomization  
594 Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.  
595 Front Neurosci. 2022;16:817067. Epub 20220301. doi: 10.3389/fnins.2022.817067. PubMed  
596 PMID: 35299622; PubMed Central PMCID: PMCPMC8920987.
- 597 18. Zhu G, Zhou S, Xu Y, Gao R, Zhang M, Zeng Q, et al. Chickenpox and multiple sclerosis:  
598 A Mendelian randomization study. J Med Virol. 2023;95(1):e28315. Epub 20221123. doi:  
599 10.1002/jmv.28315. PubMed PMID: 36380510.
- 600 19. Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic  
601 Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A  
602 Genome-Wide and HLA Association Study. Open Forum Infect Dis. 2020;7(11):ofaa450.  
603 Epub 20200924. doi: 10.1093/ofid/ofaa450. PubMed PMID: 33204752; PubMed Central  
604 PMCID: PMCPMC7641500.
- 605 20. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in  
606 susceptibility. Science. 2019;365(6460). doi: 10.1126/science.aav7188. PubMed PMID:  
607 31604244; PubMed Central PMCID: PMCPMC7241648.
- 608 21. Estrada K, Whelan CW, Zhao F, Bronson P, Handsaker RE, Sun C, et al. A whole-  
609 genome sequence study identifies genetic risk factors for neuromyelitis optica. Nat Commun.  
610 2018;9(1):1929. Epub 20180516. doi: 10.1038/s41467-018-04332-3. PubMed PMID:  
611 29769526; PubMed Central PMCID: PMCPMC5955905.
- 612 22. Chia R, Saez-Atienzar S, Murphy N, Chiò A, Blauwendraat C, Roda RH, et al.

613 Identification of genetic risk loci and prioritization of genes and pathways for myasthenia  
614 gravis: a genome-wide association study. Proc Natl Acad Sci U S A. 2022;119(5). doi:  
615 10.1073/pnas.2108672119. PubMed PMID: 35074870; PubMed Central PMCID:  
616 PMCPMC8812681.

617 23. Jiang L, Zheng Z, Fang H, Yang J. A generalized linear mixed model association tool for  
618 biobank-scale data. Nat Genet. 2021;53(11):1616-21. Epub 20211104. doi: 10.1038/s41588-  
619 021-00954-4. PubMed PMID: 34737426.

620 24. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with  
621 multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658-65. Epub  
622 20130920. doi: 10.1002/gepi.21758. PubMed PMID: 24114802; PubMed Central PMCID:  
623 PMCPMC4377079.

624 25. Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A multivariate  
625 genome-wide association analysis of 10 LDL subfractions, and their response to statin  
626 treatment, in 1868 Caucasians. PLoS One. 2015;10(4):e0120758. Epub 20150421. doi:  
627 10.1371/journal.pone.0120758. PubMed PMID: 25898129; PubMed Central PMCID:  
628 PMCPMC4405269.

629 26. Sekula P, Del Greco MF, Pattaro C, Köttgen A. Mendelian Randomization as an  
630 Approach to Assess Causality Using Observational Data. J Am Soc Nephrol.  
631 2016;27(11):3253-65. Epub 20160802. doi: 10.1681/asn.2016010098. PubMed PMID:  
632 27486138; PubMed Central PMCID: PMCPMC5084898.

633 27. Sedgwick P. Multiple hypothesis testing and Bonferroni's correction. Bmj.  
634 2014;349:g6284. Epub 20141020. doi: 10.1136/bmj.g6284. PubMed PMID: 25331533.



- 635 28. Middeldorp JM, Brink AA, van den Brule AJ, Meijer CJ. Pathogenic roles for Epstein-Barr  
636 virus (EBV) gene products in EBV-associated proliferative disorders. *Crit Rev Oncol Hematol*.  
637 2003;45(1):1-36. doi: 10.1016/s1040-8428(02)00078-1. PubMed PMID: 12482570.
- 638 29. Zhang Q, Holley-Guthrie E, Ge JQ, Dorsky D, Kenney S. The Epstein-Barr virus (EBV)  
639 DNA polymerase accessory protein, BMRF1, activates the essential downstream component  
640 of the EBV oriLyf. *Virology*. 1997;230(1):22-34. doi: 10.1006/viro.1997.8470. PubMed PMID:  
641 9126259.
- 642 30. Dooley MM, de Gannes SL, Fu KA, Lindsey JW. The increased antibody response to  
643 Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins. *J Neuroimmunol*.  
644 2016;299:147-51. Epub 20160831. doi: 10.1016/j.jneuroim.2016.08.016. PubMed PMID:  
645 27725113.
- 646 31. Huang J, Tengvall K, Bomfim Lima I, Hedström AK, Butt J, Brenner N, et al. Genetics of  
647 immune response to Epstein-Barr virus: prospects for multiple sclerosis pathogenesis. *Brain*.  
648 2024. Epub 20240417. doi: 10.1093/brain/awae110. PubMed PMID: 38630618.
- 649 32. Domínguez-Mozo MI, López-Lozano L, Pérez-Pérez S, García-Martínez Á, Torrejón MJ,  
650 Arroyo R, Álvarez-Lafuente R. Epstein-Barr Virus and multiple sclerosis in a Spanish cohort:  
651 A two-years longitudinal study. *Front Immunol*. 2022;13:991662. Epub 20220914. doi:  
652 10.3389/fimmu.2022.991662. PubMed PMID: 36189297; PubMed Central PMCID:  
653 PMCPMC9515943.
- 654 33. Bray PF, Luka J, Bray PF, Culp KW, Schlight JP. Antibodies against Epstein-Barr  
655 nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities  
656 between EBNA and myelin basic protein. *Neurology*. 1992;42(9):1798-804. doi:

- 657 10.1212/wnl.42.9.1798. PubMed PMID: 1381067.
- 658 34. Lanz TV, Brewer RC, Ho PP, Moon JS, Jude KM, Fernandez D, et al. Clonally expanded  
659 B cells in multiple sclerosis bind EBV EBNA1 and GialCAM. *Nature*. 2022;603(7900):321-7.  
660 Epub 20220124. doi: 10.1038/s41586-022-04432-7. PubMed PMID: 35073561; PubMed  
661 Central PMCID: PMCPMC9382663.
- 662 35. Kylesbech C, Trier N, Slibinskas R, Ciplys E, Tsakiri A, Frederiksen JL, Houen G. Virus-  
663 specific antibody indices may supplement the total IgG index in diagnostics of multiple  
664 sclerosis. *J Neuroimmunol*. 2022;367:577868. Epub 20220418. doi:  
665 10.1016/j.jneuroim.2022.577868. PubMed PMID: 35477126.
- 666 36. Lindsey JW. Antibodies to the Epstein-Barr virus proteins BFRF3 and BRRF2 cross-react  
667 with human proteins. *J Neuroimmunol*. 2017;310:131-4. Epub 20170720. doi:  
668 10.1016/j.jneuroim.2017.07.013. PubMed PMID: 28778437.
- 669 37. Kühlenbäumer G, Hannibal MC, Nelis E, Schirmacher A, Verpoorten N, Meuleman J, et  
670 al. Mutations in SEPT9 cause hereditary neuralgic amyotrophy. *Nat Genet*.  
671 2005;37(10):1044-6. Epub 20050925. doi: 10.1038/ng1649. PubMed PMID: 16186812.
- 672 38. Mao H, Liu J, Shi W, Huang Q, Xu X, Ni L, et al. The expression patterns of Septin-9  
673 after traumatic brain injury in rat brain. *J Mol Neurosci*. 2013;51(2):558-66. Epub 20130523.  
674 doi: 10.1007/s12031-013-0024-6. PubMed PMID: 23700216.
- 675 39. Tengvall K, Huang J, Hellström C, Kammer P, Biström M, Ayoglu B, et al. Molecular  
676 mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with  
677 multiple sclerosis risk. *Proc Natl Acad Sci U S A*. 2019;116(34):16955-60. Epub 20190802.  
678 doi: 10.1073/pnas.1902623116. PubMed PMID: 31375628; PubMed Central PMCID:

- 679 PMCPMC6708327.
- 680 40. Sherbet GV. Molecular Approach to Targeted Therapy for Multiple Sclerosis. CNS Neurol  
681 Disord Drug Targets. 2016;15(1):20-34. doi: 10.2174/1871527315666151110125840.  
682 PubMed PMID: 26560895.
- 683 41. Moreno MA, Or-Geva N, Aftab BT, Khanna R, Croze E, Steinman L, Han MH. Molecular  
684 signature of Epstein-Barr virus infection in MS brain lesions. Neurol Neuroimmunol  
685 Neuroinflamm. 2018;5(4):e466. Epub 20180607. doi: 10.1212/nxi.0000000000000466.  
686 PubMed PMID: 29892607; PubMed Central PMCID: PMCPMC5994704.
- 687 42. Osipova-Goldberg HI, Turchanowa LV, Adler B, Pfeilschifter JM. H<sub>2</sub>O<sub>2</sub> inhibits BCR-  
688 dependent immediate early induction of EBV genes in Burkitt's lymphoma cells. Free Radic  
689 Biol Med. 2009;47(8):1120-9. Epub 20090621. doi: 10.1016/j.freeradbiomed.2009.06.019.  
690 PubMed PMID: 19540913.
- 691 43. Maple PAC, Gran B, Tanasescu R, Pritchard DI, Constantinescu CS. An Absence of  
692 Epstein-Barr Virus Reactivation and Associations with Disease Activity in People with Multiple  
693 Sclerosis Undergoing Therapeutic Hookworm Vaccination. Vaccines (Basel). 2020;8(3). Epub  
694 20200828. doi: 10.3390/vaccines8030487. PubMed PMID: 32872342; PubMed Central  
695 PMCID: PMCPMC7564729.
- 696 44. Torkildsen Ø, Nyland H, Myrmed H, Myhr KM. Epstein-Barr virus reactivation and multiple  
697 sclerosis. Eur J Neurol. 2008;15(1):106-8. Epub 20071127. doi: 10.1111/j.1468-  
698 1331.2007.02009.x. PubMed PMID: 18042233.
- 699 45. Yea C, Tellier R, Chong P, Westmacott G, Marrie RA, Bar-Or A, Banwell B. Epstein-Barr  
700 virus in oral shedding of children with multiple sclerosis. Neurology. 2013;81(16):1392-9.

701 Epub 20130906. doi: 10.1212/WNL.0b013e3182a841e4. PubMed PMID: 24014504; PubMed  
702 Central PMCID: PMCPMC3806908.

703 46. Massa J, Munger KL, O'Reilly EJ, Falk KI, Ascherio A. Plasma titers of antibodies against  
704 Epstein-Barr virus BZLF1 and risk of multiple sclerosis. *Neuroepidemiology*. 2007;28(4):214-5.  
705 Epub 20070911. doi: 10.1159/000108113. PubMed PMID: 17851260.

706 47. Masuda S, Mori M, Arai K, Uzawa A, Muto M, Uchida T, et al. Epstein-Barr virus  
707 persistence and reactivation in neuromyelitis optica. *J Neurol Neurosurg Psychiatry*.  
708 2015;86(10):1137-42. Epub 20141128. doi: 10.1136/jnnp-2014-308095. PubMed PMID:  
709 25433035.

710 48. Shi Z, Kong L, Wang R, Wang X, Wang Z, Luo W, et al. Cytomegalovirus and Epstein-  
711 Barr virus infections in patients with neuromyelitis optica spectrum disorder. *J Neurol*. 2024.  
712 Epub 20240724. doi: 10.1007/s00415-024-12571-2. PubMed PMID: 39046523.

713 49. Graves J, Grandhe S, Weinfurter K, Krupp L, Belman A, Chitnis T, et al. Protective  
714 environmental factors for neuromyelitis optica. *Neurology*. 2014;83(21):1923-9. Epub  
715 20141022. doi: 10.1212/wnl.0000000000001001. PubMed PMID: 25339213; PubMed Central  
716 PMCID: PMCPMC4248458.

717 50. Merelli E, Bedin R, Sola P, Barozzi P, Mancardi GL, Ficarra G, Franchini G. Human  
718 herpes virus 6 and human herpes virus 8 DNA sequences in brains of multiple sclerosis  
719 patients, normal adults and children. *J Neurol*. 1997;244(7):450-4. doi:  
720 10.1007/s004150050121. PubMed PMID: 9266465.

721 51. Nora-Krukle Z, Chapenko S, Logina I, Millers A, Platkajis A, Murovska M. Human  
722 herpesvirus 6 and 7 reactivation and disease activity in multiple sclerosis. *Medicina (Kaunas)*.

- 723 2011;47(10):527-31. PubMed PMID: 22186115.
- 724 52. Khalesi Z, Tamrchi V, Razizadeh MH, Letafati A, Moradi P, Habibi A, et al. Association  
725 between human herpesviruses and multiple sclerosis: A systematic review and meta-analysis.  
726 Microb Pathog. 2023;177:106031. Epub 20230210. doi: 10.1016/j.micpath.2023.106031.  
727 PubMed PMID: 36775211.
- 728 53. Thakolwiboon S, Zhao-Fleming H, Karukote A, Pachariyanon P, Williams HG, Avila M.  
729 Regional differences in the association of cytomegalovirus seropositivity and multiple  
730 sclerosis: A systematic review and meta-analysis. Mult Scler Relat Disord. 2020;45:102393.  
731 Epub 20200712. doi: 10.1016/j.msard.2020.102393. PubMed PMID: 32683307.
- 732 54. Heerlein K, Jarius S, Jacobi C, Rohde S, Storch-Hagenlocher B, Wildemann B.  
733 Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella  
734 zoster infection. J Neurol Sci. 2009;276(1-2):184-6. Epub 20080920. doi:  
735 10.1016/j.jns.2008.08.015. PubMed PMID: 18805556.
- 736 55. Sellner J, Hemmer B, Mühlau M. The clinical spectrum and immunobiology of  
737 parainfectious neuromyelitis optica (Devic) syndromes. J Autoimmun. 2010;34(4):371-9. Epub  
738 20091022. doi: 10.1016/j.jaut.2009.09.013. PubMed PMID: 19853412.
- 739 56. Machado C, Amorim J, Rocha J, Pereira J, Lourenço E, Pinho J. Neuromyelitis optica  
740 spectrum disorder and varicella-zoster infection. J Neurol Sci. 2015;358(1-2):520-1. Epub  
741 20151004. doi: 10.1016/j.jns.2015.09.374. PubMed PMID: 26440423.
- 742 57. Wang L, Zhou L, Zhang Bao J, Huang W, Tan H, Fan Y, et al. Causal associations  
743 between prodromal infection and neuromyelitis optica spectrum disorder: A Mendelian  
744 randomization study. Eur J Neurol. 2023;30(12):3819-27. Epub 20230816. doi:

745 10.1111/ene.16014. PubMed PMID: 37540821.

746




Fig 1 MR estimate results of antibodies of five herpesviridae viruses




Fig 2 MR estimate results of antibodies of five herpesviridae virus






Fig 3 MR estimate results of antibodies of five herpesviridae viru




Fig 4 MR estimate results of antibodies of five herpesviridae viru




Fig 5 MR estimate results of antibodies of five herpesviridae viru